Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 11, 23 | 41.50 Increased by +21.94 K% | 4.50 Increased by +822.22% |
| May 11, 23 | -0.20 Increased by +25.93% | -0.19 Decreased by -5.26% |
| Mar 14, 23 | -0.31 Increased by +16.22% | -0.20 Decreased by -55.00% |
| Mar 2, 23 | -0.18 Increased by +41.94% | -0.20 Increased by +10.00% |
| Nov 3, 22 | -0.19 Increased by +38.71% | -0.23 Increased by +17.39% |
| Aug 4, 22 | -0.27 Decreased by -170.00% | -0.31 Increased by +12.90% |
| May 5, 22 | -0.37 Decreased by -32.14% | -0.34 Decreased by -8.82% |
| Mar 8, 22 | -0.31 Increased by +11.43% | -0.29 Decreased by -6.90% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 688.00 K Increased by +10.08% | -217.08 M Decreased by -872.45% | Decreased by -31.55 K% Decreased by -783.41% |
| Mar 31, 23 | 198.00 K Decreased by -85.46% | -18.42 M Increased by +24.60% | Decreased by -9.30 K% Decreased by -418.69% |
| Dec 31, 22 | 168.00 K Decreased by -95.39% | -18.82 M Increased by +7.94% | Decreased by -11.20 K% Decreased by -1.90 K% |
| Sep 30, 22 | 174.00 K Decreased by -87.56% | -18.23 M Increased by +10.21% | Decreased by -10.48 K% Decreased by -621.95% |
| Jun 30, 22 | 625.00 K Decreased by -95.44% | -22.32 M Decreased by -226.84% | Decreased by -3.57 K% Decreased by -7.06 K% |
| Mar 31, 22 | 1.36 M Increased by +N/A% | -24.43 M Decreased by -34.10% | Decreased by -1.79 K% Decreased by N/A% |
| Dec 31, 21 | 3.64 M Increased by +N/A% | -20.45 M Increased by +9.99% | Decreased by -561.09% Decreased by N/A% |
| Sep 30, 21 | 1.40 M Increased by +N/A% | -20.31 M Decreased by -12.61% | Decreased by -1.45 K% Decreased by N/A% |
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.